Operating cash flow of $4.5B in 2026Q3 implied a 2.83x conversion of net income, but quarterly free cash flow margins swung from 3.6% to 16.3% and buybacks of $3.0B consumed most surplus cash, warranting caution about run-rate durability.
HCA Healthcare, Inc. (HCA) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 11.17B | 12.64B | 10.51B | 9.43B | 8.52B | 8.96B | 9.23B | 7.6B | 6.76B | 5.43B | 5.65B | 4.73B | 4.45B | 3.68B | 4.17B | 3.93B | 3.08B | 2.75B | 1.8B | 1.4B | 1.84B | 3.16B | 3.05B | 2.17B | 2.75B | 1.41B | 1.55B | 1.22B | 1.92B | 1.48B | 2.62B |
| Operating CF Margin % | - | 16.71% | 14.89% | 14.52% | 14.15% | 15.25% | 17.91% | 14.81% | 14.48% | 12.44% | 13.63% | 11.93% | 12.05% | 10.77% | 12.65% | 12.1% | 10.05% | 9.14% | 6.33% | 5.2% | 7.24% | 12.92% | 12.97% | 9.93% | 13.94% | 7.87% | 9.28% | 7.34% | 10.26% | 7.88% | 13.16% |
| Operating CF Growth % | -29.35% | 20.18% | 11.48% | 10.67% | -4.88% | -2.96% | 21.44% | 12.44% | 24.6% | -4.02% | 19.41% | 6.43% | 20.87% | -11.86% | 6.15% | 27.49% | 12.3% | 52.87% | 28.72% | -24.34% | -41.6% | 3.61% | 40.77% | -21.24% | 94.62% | -8.66% | 26.49% | -36.17% | 29.2% | -43.42% | 16.28% |
| Net Income | 6.78B | 6.78B | 6.66B | 5.24B | 6.83B | 7.72B | 4.39B | 4.14B | 4.39B | 2.74B | 3.43B | 2.7B | 2.37B | 2B | 2.01B | 2.84B | 1.57B | 1.38B | 673M | 874M | 1.04B | 1.42B | 1.25B | 1.33B | 833M | 886M | 219M | 657M | 532M | 126M | 1.5B |
| Depreciation & Amortization | 3.74B | 3.52B | 3.31B | 3.08B | 2.97B | 2.85B | 2.72B | 2.6B | 2.28B | 2.13B | 1.97B | 1.9B | 1.82B | 1.75B | 1.68B | 1.47B | 1.42B | 1.43B | 1.42B | 1.43B | 1.39B | 1.37B | 1.25B | 1.11B | 1.01B | 1.05B | 1.03B | 1.09B | 1.25B | 1.24B | 1.16B |
| Stock-Based Compensation | 0 | 0 | 360M | 0 | 341M | 440M | 362M | 347M | 268M | 270M | 251M | 239M | 163M | 113M | 56M | 26M | 32M | 40M | 32M | 24M | 324M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 22M | 229M | 571M | -70M | 41M | 250M | 74M | 433M | 123M | -160M | -83M | 143M | 96M | 1.71B | 2.85B | 169M | 2.78B | 1.81B | 1.44B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -163M | 0 |
| Other Non-Cash Items | -404M | 1.6B | 269M | 1.34B | -1.04B | -1.48B | 443M | 352M | -281M | 145M | -161M | 378M | 439M | 89M | 231M | 842M | 58M | 2.83B | 261M | 878M | 591M | 2.64B | 3.13B | 1.86B | 2.54B | 1.08B | 2.03B | 1.16B | 1.58B | 1.92B | 71M |
| Working Capital Changes | 1.06B | 728M | -106M | -457M | -1.15B | -503M | 1.28B | -88M | 33M | -296M | 42M | -323M | -264M | -414M | 107M | -2.95B | -2.85B | -3.09B | -3.37B | -3.62B | -2.94B | -2.28B | -2.58B | -2.14B | -1.63B | -1.6B | -1.74B | -1.69B | -1.45B | -1.64B | -110M |
| Change in Receivables | -1.07B | -94M | -799M | -935M | -797M | -962M | 327M | -326M | -423M | -4.64B | -3.25B | -4.11B | -3.65B | -4.39B | -3.9B | -3.25B | -2.79B | -3.18B | -3.33B | 0 | 0 | -2.65B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 53M | -154M | 334M | -126M | -59M | -540M | -304M | -158M | -242M | -69M | -112M | -314M | -232M | -19M | -122M | -18M | -287M | -191M | 159M | -241M | -12M | 28M | -46M | 32M | -88M | -39M | 90M | -119M | -39M | 25M | -29M |
| Change in Payables | 967M | 666M | 359M | 604M | -296M | 999M | 1.25B | 396M | 698M | 374M | 144M | 192M | 3.88B | 4.41B | 4.02B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -6.07B | -4.99B | -4.93B | -5.32B | -3.39B | -2.64B | -3.39B | -5.72B | -3.9B | -4.28B | -3.24B | -2.58B | -2.92B | -2.35B | -2.06B | -3B | -1.04B | -1.03B | -1.47B | -479M | -1.31B | -1.68B | -1.69B | -2.86B | -1.74B | -1.3B | -1.09B | 925M | 970M | -2.75B | -2.25B |
| Capital Expenditures | -5.2B | -4.94B | -4.88B | -4.74B | -4.39B | -3.58B | -2.83B | -4.16B | -3.57B | -3.02B | -2.76B | -2.38B | -2.18B | -1.94B | -1.86B | -1.68B | -1.32B | -1.32B | -1.6B | -1.44B | -1.86B | -1.59B | -1.51B | -1.84B | -1.72B | -1.37B | -1.16B | -1.29B | -1.25B | -1.42B | -1.4B |
| CapEx % of Revenue | 6.6% | 6.54% | 6.9% | 7.3% | 7.3% | 6.09% | 5.5% | 8.1% | 7.65% | 6.91% | 6.65% | 5.99% | 5.89% | 5.68% | 5.64% | 5.17% | 4.32% | 4.38% | 5.64% | 5.38% | 7.32% | 6.51% | 6.44% | 8.43% | 8.71% | 7.63% | 6.93% | 7.73% | 6.72% | 7.56% | 7.03% |
| Acquisitions | -779M | -128M | 62M | -442M | 1.01B | 1.05B | -500M | -1.62B | -445M | -1.21B | -576M | -278M | -715M | -448M | -228M | -1.4B | -196M | -20M | 108M | 735M | 539M | 194M | 4M | -745M | 11M | 280M | -23M | 805M | 1.84B | -411M | -816M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -58M | 12M | -120M | -131M | -7M | -121M | -58M | 59M | 60M | -52M | 96M | 70M | -27M | 45M | 27M | 85M | 482M | -1M | 25M | 230M | 19M | -283M | -179M | -279M | -33M | -210M | 91M | 1.41B | 674M | -1.05B | 185M |
| Cash from Financing | -5.18B | -8.55B | -4.58B | -4.09B | -5.66B | -6.66B | -4.68B | -1.77B | -3.08B | -1.06B | -2.51B | -1.98B | -1.38B | -1.63B | -1.78B | -976M | -1.95B | -1.86B | -258M | -1.16B | -240M | -1.4B | -1.35B | 650M | -934M | -342M | -336M | -2.25B | -2.7B | 1.26B | -489M |
| Debt Issued (Net) | 5.73B | 3.21B | 3.21B | 1.29B | 3.29B | 3.25B | -3.22B | 567M | -344M | 1.51B | 815M | 778M | 778M | -692M | 1.72B | -1.59B | 2.53B | -1.53B | -260M | -1.25B | 17.59B | -106M | 1.78B | 1.57B | -466M | 608M | 922M | -535M | -2.66B | 2.38B | -423M |
| Equity Issued (Net) | -9.16B | -10.07B | -6.04B | -3.81B | -7B | -8.21B | -441M | -1.03B | -1.53B | -2.05B | -2.75B | -2.4B | -1.75B | -500M | 0 | 1B | 0 | 0 | 0 | 100M | -20.91B | -847M | -2.88B | -949M | -15M | -1.29B | -677M | -1.88B | 8M | -1.08B | 0 |
| Dividends Paid | -681M | -679M | -690M | -661M | -653M | -624M | -153M | -550M | -487M | 0 | 0 | 0 | -7M | -16M | -3.15B | -31M | -4.26B | 0 | 0 | 0 | -201M | -258M | -199M | -39M | -40M | -42M | -44M | 0 | 0 | 0 | -54M |
| Share Repurchases | -9.16B | -10.07B | -6.04B | -3.81B | -7B | -8.21B | -441M | -1.03B | -1.53B | -2.05B | -2.75B | -2.4B | -1.75B | -500M | 0 | -1.5B | 0 | 0 | 0 | 0 | -21.02B | -1.86B | -3.11B | -1.11B | -282M | -1.51B | 0 | 0 | 0 | -1.08B | 0 |
| Other Financing | -1.07B | -1.01B | -1.05B | -917M | -1.29B | -1.07B | -866M | -757M | -714M | -519M | -572M | -357M | -399M | -417M | -356M | -359M | -223M | -336M | 2M | -3M | 3.27B | -189M | -41M | 65M | -413M | 385M | -537M | 164M | -49M | -42M | -12M |
| Net Change in Cash | -89M | -893M | 998M | 27M | -543M | -342M | 1.17B | 119M | -230M | 86M | -95M | 175M | 152M | -291M | 332M | -38M | 99M | -153M | 72M | -241M | 298M | 78M | 14M | -46M | 76M | -229M | 124M | -107M | 187M | -3M | -119M |
| Free Cash Flow | 5.97B | 7.69B | 5.64B | 4.69B | 4.13B | 5.38B | 6.4B | 3.44B | 3.19B | 2.41B | 2.89B | 2.36B | 2.27B | 1.74B | 2.31B | 2.25B | 1.76B | 1.43B | 197M | -48M | -20M | 1.57B | 1.54B | 328M | 1.03B | 43M | 392M | -64M | 661M | 61M | 1.22B |
| FCF Margin % | 7.59% | 10.17% | 7.99% | 7.21% | 6.85% | 9.16% | 12.41% | 6.71% | 6.83% | 5.53% | 6.97% | 5.95% | 6.15% | 5.08% | 7.01% | 6.93% | 5.74% | 4.76% | 0.69% | -0.18% | -0.08% | 6.41% | 6.54% | 1.5% | 5.23% | 0.24% | 2.35% | -0.38% | 3.54% | 0.32% | 6.13% |
| FCF Growth % | -26.22% | 36.41% | 20.31% | 13.57% | -23.32% | -15.87% | 85.74% | 8.03% | 32.23% | -16.66% | 22.64% | 3.83% | 30.8% | -24.9% | 2.62% | 28.07% | 23.08% | 625.89% | 510.42% | -140% | -101.28% | 2.02% | 368.29% | -68.22% | 2300% | -89.03% | 712.5% | -109.68% | 983.61% | -95% | 67.95% |
| FCF per Share | 27.50 | 33.34 | 21.54 | 16.96 | 14.01 | 16.37 | 18.52 | 9.89 | 8.97 | 6.48 | 7.31 | 5.53 | 5.04 | 3.76 | 5.03 | 4.54 | 4.02 | 4.10 | 0.56 | -0.14 | -0.05 | 3.50 | 3.18 | 0.64 | 1.97 | 0.08 | 0.71 | -0.10 | 1.02 | 0.09 | 1.80 |
| FCF Conversion (FCF/Net Income) | 0.88x | 1.86x | 1.83x | 1.80x | 1.51x | 1.29x | 2.46x | 2.17x | 1.79x | 2.45x | 1.96x | 2.22x | 2.37x | 2.37x | 2.60x | 1.60x | 2.56x | 2.61x | 2.67x | 1.60x | 1.78x | 2.22x | 2.45x | 1.63x | 3.30x | 1.59x | 5.30x | 1.65x | 4.07x | -4.86x | 1.74x |
| Interest Paid | 1.08B | 2.21B | 1.94B | 1.89B | 1.66B | 1.5B | 1.61B | 1.91B | 1.74B | 1.7B | 1.67B | 1.65B | 1.76B | 1.83B | 1.72B | 1.99B | 1.99B | 1.75B | 1.98B | 2.16B | 893M | 624M | 533M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.84B | 1.39B | 1.18B | 2.18B | 1B | 849M | 872M | 1.21B | 1.25B | 1.19B | 1.06B | 694M | 618M | 256M | 517M | 1.15B | 716M | 421M | 1.09B | 563M | 394M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying HCA stock.
HCA Healthcare, Inc. (HCA) generated $12.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
HCA Healthcare, Inc. (HCA) generated $7.69B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
HCA Healthcare, Inc. (HCA) spent $4.94B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, HCA Healthcare, Inc. (HCA) returned $679.0M to shareholders via cash dividends and spent $10.07B on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Working capital-driven cash volatility
Metrics are mathematically derived from official filings.
Operating Cash Flow Outpacing Reported Earnings
According to reported quarterly figures, HCA's operating cash flow ran at roughly 1.0x to 2.8x net income across the ten quarters shown, with the 2026Q3 ratio of 2.83 reflecting unusually strong collections rather than a repeatable earnings base.
The gap between net income and operating cash flow is wide and uneven, which suggests quarterly cash generation is driven heavily by working capital timing rather than steady earnings conversion. Ratios near 1.0x in 2025Q1 and 2026Q1 indicate that when working capital reverses, operating cash flow compresses sharply toward net income. Investors should treat the high-conversion quarters with caution and monitor whether the working capital swings reflect durable collections improvement or temporary timing effects.
Working Capital Swings Drive Cash Volatility
As reported in financial statements, HCA's working capital changes ranged from a $1.7B outflow in 2025Q1 to a $2.3B inflow in 2025Q3, a swing large enough to dominate quarterly operating cash flow.
These alternating inflows and outflows suggest receivables collection and payables timing exert greater influence on reported cash generation than underlying operating profitability. The pattern implies that quarterly free cash flow figures should be read on a trailing-twelve-month basis to avoid misjudging the cash run-rate. Analysts should watch whether the outflow quarters reflect accumulating receivables, which may warrant further investigation into collection efficiency.
Free Cash Flow Margins Remain Highly Uneven
Based on reported figures, HCA's free cash flow margin varied from 3.6% in 2025Q1 to 16.3% in 2025Q2 and 2025Q3, indicating that quarterly FCF is an unreliable single-period indicator for this business.
Averaging the reported quarters suggests a mid-single-digit to high-single-digit normalized FCF margin, which is more informative than any individual period. The trajectory does not show a clear secular trend across the ten quarters, pointing to a business whose cash output depends heavily on timing. Relative to the peer set, HCA's underlying cash margin appears broadly in line with UHS, though the quarterly noise warrants caution.
Capital Intensity Steady at Six to Eight Percent
According to recent SEC filings, HCA's capital expenditures consistently ran between 5.4% and 7.6% of revenue, reflecting the ongoing maintenance and modernization demands of an acute care hospital footprint.
Capex intensity of this magnitude is typical for a hospital operator, and the steady level suggests facility investment is not being cut to inflate free cash flow. Depreciation and amortization of roughly $0.8B to $1.0B per quarter exceeds the reported capex in most periods, which may indicate the asset base is being maintained at a pace that roughly matches wear. Investors should monitor whether capex stays disciplined enough to protect margins in competitive markets.
Buybacks Absorb Surplus Cash Flow
As reported in financial statements, HCA deployed between $1.4B and $3.0B per quarter into share repurchases, consuming most of the free cash flow generated in strong quarters and funding these returns partly through balance sheet capacity.
Repurchases at this pace appear to exceed free cash flow in several quarters, suggesting buybacks are supported by the cash generation in high-conversion periods rather than by steady earnings alone. Dividends of roughly $165M to $183M per quarter are modest by comparison, indicating capital return is weighted toward repurchases. This allocation may enhance per-share metrics but leaves limited cushion if working capital reverses during a period of softer demand.
Headline Cash Strength May Overstate Durability
As reported in financial statements, HCA's strongest quarters, including 2026Q3 with $4.5B operating cash flow, coincide with large working capital inflows, which may indicate that peak cash output is not a reliable run-rate.
Reading the cash flow statement at face value risks mistaking timing benefits for structural improvement, since the quarters with the highest conversion ratios are also those with the largest working capital releases. Stock-based compensation is reported as zero in most periods, so no non-cash equity adjustment is visible in the supplied data, and data is unavailable to assess capitalized costs or off-balance sheet obligations. Investors should warrant further investigation into whether the collection and payables effects reverse in subsequent periods.